Literature DB >> 17382374

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

James A McCubrey1, Linda S Steelman, Richard A Franklin, Steven L Abrams, William H Chappell, Ellis W T Wong, Brian D Lehmann, David M Terrian, Jorg Basecke, Franca Stivala, Massimo Libra, Camilla Evangelisti, Alberto M Martelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17382374      PMCID： PMC2696319          DOI： 10.1016/j.advenzreg.2006.12.013

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN： 0065-2571


× No keyword cloud information.
  271 in total

Review 1.  The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology.

Authors:  T E Parry
Journal:  Leuk Res       Date:  1997-06       Impact factor: 3.156

2.  Interleukin 3-dependent survival by the Akt protein kinase.

Authors:  Z Songyang; D Baltimore; L C Cantley; D R Kaplan; T F Franke
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 3.  Phosphoinositide 3-kinase: from viral oncoprotein to drug target.

Authors:  Peter K Vogt; Andreas G Bader; Sohye Kang
Journal:  Virology       Date:  2006-01-05       Impact factor: 3.616

4.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.

Authors:  Akira Shimada; Tomohiko Taki; Ken Tabuchi; Akio Tawa; Keizo Horibe; Masahiro Tsuchida; Ryoji Hanada; Ichiro Tsukimoto; Yasuhide Hayashi
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

5.  Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

Authors:  S R Datta; H Dudek; X Tao; S Masters; H Fu; Y Gotoh; M E Greenberg
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

6.  ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter.

Authors:  R S Thomas; M J Tymms; L H McKinlay; M F Shannon; A Seth; I Kola
Journal:  Oncogene       Date:  1997-06-12       Impact factor: 9.867

7.  Role of extracellular signal-regulated protein kinases in apoptosis by asbestos and H2O2.

Authors:  L A Jiménez; C Zanella; H Fung; Y M Janssen; P Vacek; C Charland; J Goldberg; B T Mossman
Journal:  Am J Physiol       Date:  1997-11

8.  Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function.

Authors:  Xiao-Jun Qi; Gary M Wildey; Philip H Howe
Journal:  J Biol Chem       Date:  2005-11-10       Impact factor: 5.157

9.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

Authors:  L del Peso; M González-García; C Page; R Herrera; G Nuñez
Journal:  Science       Date:  1997-10-24       Impact factor: 47.728

10.  Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML.

Authors:  A Hiramatsu; H Miwa; M Shikami; T Ikai; E Tajima; H Yamamoto; N Imai; A Hattori; T Kyo; M Watarai; K Miura; A Satoh; M Itoh; A Imamura; H Mihara; Y Katoh; M Nitta
Journal:  Leuk Lymphoma       Date:  2006-01
View more
  32 in total

1.  Dusp5 negatively regulates IL-33-mediated eosinophil survival and function.

Authors:  Derek A Holmes; Jung-Hua Yeh; Donghong Yan; Min Xu; Andrew C Chan
Journal:  EMBO J       Date:  2014-11-14       Impact factor: 11.598

2.  Increased activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis.

Authors:  Xunqin Yin; Mary Ellen Pavone; Zhenxiao Lu; JianJun Wei; J Julie Kim
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  Transcriptional repression of Mad-Max complex by human umbilical cord blood stem cells downregulates extracellular signal-regulated kinase in glioblastoma.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Andrew J Tsung; Dzung H Dinh; Jasti S Rao
Journal:  Stem Cells Dev       Date:  2011-11-21       Impact factor: 3.272

Review 4.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

Review 5.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

6.  Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Authors:  Neeraj Kapur; Hina Mir; Guru P Sonpavde; Sanjay Jain; Sejong Bae; James W Lillard; Shailesh Singh
Journal:  Cancer Lett       Date:  2019-04-08       Impact factor: 8.679

7.  siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma.

Authors:  Ganji Purna Chandra Nagaraju; Arun Kumar Nalla; Reshu Gupta; Sanjeeva Mohanam; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  Mol Cancer Res       Date:  2010-12-10       Impact factor: 5.852

8.  The expression of survivin and its related genes in adipocyte-derived stem cell by demethylation.

Authors:  Kwang Yoon; Young Soo Lim; Soo Bong Yu; Doo Sik Kim; Sie Jeong Ryu; Kyung Han Kim; Tae Ho Jang; Se Hwan Kim
Journal:  Korean J Anesthesiol       Date:  2010-04-28

9.  Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways.

Authors:  Toshihiro Shimizu; Atsushi Kasamatsu; Ayumi Yamamoto; Kazuyuki Koike; Shunsaku Ishige; Hiroaki Takatori; Yosuke Sakamoto; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

10.  A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling.

Authors:  B F Clem; A L Clem; A Yalcin; U Goswami; S Arumugam; S Telang; J O Trent; J Chesney
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.